Skip to main content
. 2008 Aug 27;5:23. doi: 10.1186/1743-7075-5-23

Figure 6.

Figure 6

Antagonists of GPR142 are candidate future obesity drugs. Anti-sense knockdown of G-protein coupled receptor gene products the loss of function previously determined to cause decrease in fat content [12]. Incubation with the stable beta-adrenergic agonist isoproterenol is shown as a positive control causing increased lipolysis for comparison.